Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
June 14 2023 - 6:00AM
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company focused on developing innovative
treatments for cancer patients, today announced that Chandler
Robinson, MD, Monopar’s Chief Executive Officer, will participate
in a one-on-one fireside chat with Jason McCarthy, PhD, Senior
Managing Director of Equity Research, at the Maxim Group’s
Healthcare Virtual Conference on Tuesday June 20, 2023 at 1:30pm
ET.
Fireside Chat Details:Date: June 20, 2023Time:
1:30 pm ETLocation: Virtual Conference
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical
company focused on developing innovative treatments for cancer
patients. Monopar's pipeline consists of camsirubicin (Phase 1b)
for the treatment of advanced soft tissue sarcoma; MNPR-101, a
late-stage preclinical antibody for radiopharmaceutical use in
advanced cancers; and MNPR-202, an early-stage camsirubicin analog
for various cancers. For more information,
visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc. Investor Relations
Kim R. Tsuchimoto Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates: Twitter:
@MonoparTx LinkedIn: Monopar Therapeutics
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From Apr 2024 to May 2024
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From May 2023 to May 2024